Surface engineering of porous silicon to optimise therapeutic antibody loading and release

Steven J.P. McInnes, Chris T. Turner, Sameer A. Al-Bataineh, Marta J.I. Airaghi Leccardi, Yazad Irani, Keryn Williams, Allison J. Cowin, Nicolas H. Voelcker

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The proinflammatory cytokine, tumor necrosis factor-α (TNF-α), is elevated in several diseases such as uveitis, rheumatoid arthritis and non-healing chronic wounds. Adding Infliximab, a chimeric IgG1 monoclonal antibody raised against TNF-α, to chronic wound fluid can neutralise human TNF-α, thereby providing a potential therapeutic option for chronic wound healing. However, to avoid the need for repeated application in a clinical setting, and to protect the therapeutic antibody from the hostile environment of the wound, suitable delivery vehicles are required. Porous silicon (pSi) is a biodegradable high surface area material commonly employed for drug delivery applications. In this study, the use of pSi microparticles (pSi MPs) for the controlled release of Infliximab to disease environments, such as chronic wounds, is demonstrated. Surface chemistry and pore parameters for Infliximab loading are first optimised in pSi films and loading conditions are transferred to pSi MPs. Loading regimens exceeding 60 μg of Infliximab per mg of pSi are achieved. Infliximab is released with zero-order release kinetics over the course of 8 days. Critically, the released antibody remains functional and is able to sequester TNF-α over a weeklong timeframe; suitable for a clinical application in chronic wound therapy.

LanguageEnglish
Pages4123-4133
Number of pages11
JournalJournal of Materials Chemistry B
Volume3
Issue number20
DOIs
Publication statusPublished - 28 May 2015

ASJC Scopus subject areas

  • Chemistry(all)
  • Biomedical Engineering
  • Materials Science(all)

Cite this

McInnes, S. J. P., Turner, C. T., Al-Bataineh, S. A., Airaghi Leccardi, M. J. I., Irani, Y., Williams, K., ... Voelcker, N. H. (2015). Surface engineering of porous silicon to optimise therapeutic antibody loading and release. Journal of Materials Chemistry B, 3(20), 4123-4133. https://doi.org/10.1039/c5tb00397k
McInnes, Steven J.P. ; Turner, Chris T. ; Al-Bataineh, Sameer A. ; Airaghi Leccardi, Marta J.I. ; Irani, Yazad ; Williams, Keryn ; Cowin, Allison J. ; Voelcker, Nicolas H. / Surface engineering of porous silicon to optimise therapeutic antibody loading and release. In: Journal of Materials Chemistry B. 2015 ; Vol. 3, No. 20. pp. 4123-4133.
@article{1d8add4f66d2499cbe24341d183a4b83,
title = "Surface engineering of porous silicon to optimise therapeutic antibody loading and release",
abstract = "The proinflammatory cytokine, tumor necrosis factor-α (TNF-α), is elevated in several diseases such as uveitis, rheumatoid arthritis and non-healing chronic wounds. Adding Infliximab, a chimeric IgG1 monoclonal antibody raised against TNF-α, to chronic wound fluid can neutralise human TNF-α, thereby providing a potential therapeutic option for chronic wound healing. However, to avoid the need for repeated application in a clinical setting, and to protect the therapeutic antibody from the hostile environment of the wound, suitable delivery vehicles are required. Porous silicon (pSi) is a biodegradable high surface area material commonly employed for drug delivery applications. In this study, the use of pSi microparticles (pSi MPs) for the controlled release of Infliximab to disease environments, such as chronic wounds, is demonstrated. Surface chemistry and pore parameters for Infliximab loading are first optimised in pSi films and loading conditions are transferred to pSi MPs. Loading regimens exceeding 60 μg of Infliximab per mg of pSi are achieved. Infliximab is released with zero-order release kinetics over the course of 8 days. Critically, the released antibody remains functional and is able to sequester TNF-α over a weeklong timeframe; suitable for a clinical application in chronic wound therapy.",
author = "McInnes, {Steven J.P.} and Turner, {Chris T.} and Al-Bataineh, {Sameer A.} and {Airaghi Leccardi}, {Marta J.I.} and Yazad Irani and Keryn Williams and Cowin, {Allison J.} and Voelcker, {Nicolas H.}",
year = "2015",
month = "5",
day = "28",
doi = "10.1039/c5tb00397k",
language = "English",
volume = "3",
pages = "4123--4133",
journal = "Journal of Materials Chemistry B",
issn = "2050-7518",
publisher = "Royal Society of Chemistry",
number = "20",

}

McInnes, SJP, Turner, CT, Al-Bataineh, SA, Airaghi Leccardi, MJI, Irani, Y, Williams, K, Cowin, AJ & Voelcker, NH 2015, 'Surface engineering of porous silicon to optimise therapeutic antibody loading and release', Journal of Materials Chemistry B, vol. 3, no. 20, pp. 4123-4133. https://doi.org/10.1039/c5tb00397k

Surface engineering of porous silicon to optimise therapeutic antibody loading and release. / McInnes, Steven J.P.; Turner, Chris T.; Al-Bataineh, Sameer A.; Airaghi Leccardi, Marta J.I.; Irani, Yazad; Williams, Keryn; Cowin, Allison J.; Voelcker, Nicolas H.

In: Journal of Materials Chemistry B, Vol. 3, No. 20, 28.05.2015, p. 4123-4133.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Surface engineering of porous silicon to optimise therapeutic antibody loading and release

AU - McInnes, Steven J.P.

AU - Turner, Chris T.

AU - Al-Bataineh, Sameer A.

AU - Airaghi Leccardi, Marta J.I.

AU - Irani, Yazad

AU - Williams, Keryn

AU - Cowin, Allison J.

AU - Voelcker, Nicolas H.

PY - 2015/5/28

Y1 - 2015/5/28

N2 - The proinflammatory cytokine, tumor necrosis factor-α (TNF-α), is elevated in several diseases such as uveitis, rheumatoid arthritis and non-healing chronic wounds. Adding Infliximab, a chimeric IgG1 monoclonal antibody raised against TNF-α, to chronic wound fluid can neutralise human TNF-α, thereby providing a potential therapeutic option for chronic wound healing. However, to avoid the need for repeated application in a clinical setting, and to protect the therapeutic antibody from the hostile environment of the wound, suitable delivery vehicles are required. Porous silicon (pSi) is a biodegradable high surface area material commonly employed for drug delivery applications. In this study, the use of pSi microparticles (pSi MPs) for the controlled release of Infliximab to disease environments, such as chronic wounds, is demonstrated. Surface chemistry and pore parameters for Infliximab loading are first optimised in pSi films and loading conditions are transferred to pSi MPs. Loading regimens exceeding 60 μg of Infliximab per mg of pSi are achieved. Infliximab is released with zero-order release kinetics over the course of 8 days. Critically, the released antibody remains functional and is able to sequester TNF-α over a weeklong timeframe; suitable for a clinical application in chronic wound therapy.

AB - The proinflammatory cytokine, tumor necrosis factor-α (TNF-α), is elevated in several diseases such as uveitis, rheumatoid arthritis and non-healing chronic wounds. Adding Infliximab, a chimeric IgG1 monoclonal antibody raised against TNF-α, to chronic wound fluid can neutralise human TNF-α, thereby providing a potential therapeutic option for chronic wound healing. However, to avoid the need for repeated application in a clinical setting, and to protect the therapeutic antibody from the hostile environment of the wound, suitable delivery vehicles are required. Porous silicon (pSi) is a biodegradable high surface area material commonly employed for drug delivery applications. In this study, the use of pSi microparticles (pSi MPs) for the controlled release of Infliximab to disease environments, such as chronic wounds, is demonstrated. Surface chemistry and pore parameters for Infliximab loading are first optimised in pSi films and loading conditions are transferred to pSi MPs. Loading regimens exceeding 60 μg of Infliximab per mg of pSi are achieved. Infliximab is released with zero-order release kinetics over the course of 8 days. Critically, the released antibody remains functional and is able to sequester TNF-α over a weeklong timeframe; suitable for a clinical application in chronic wound therapy.

UR - http://www.scopus.com/inward/record.url?scp=84929223293&partnerID=8YFLogxK

U2 - 10.1039/c5tb00397k

DO - 10.1039/c5tb00397k

M3 - Article

VL - 3

SP - 4123

EP - 4133

JO - Journal of Materials Chemistry B

T2 - Journal of Materials Chemistry B

JF - Journal of Materials Chemistry B

SN - 2050-7518

IS - 20

ER -